Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: Proposal of reference values for defining lipodystrophy

Journal of Clinical Densitometry

Volumn 8, Issue 3, 2005, Pages 287-292

  Bonnet, E ^a   Delpierre, C ^d   Sommet, A ^a   Marion Latard, F ^b   Herve R ^a   Aquilina, C ^c   Labau, E ^a   Obadia, M ^a   Marchou, B ^a   Massip, P ^a   Perret, B ^a   Bernard, J ^b  

^a CHU PURPAN   (France)

^b CHU RANGUEIL   (France)

^c Serv Univ Psychiat l'Enfant l'A   (France)

^d INSERM   (France)

Author keywords

Antiretroviral drugs; Bone mineral density; DXA; Fat mass ratio; HIV; Lipodystrophy

Indexed keywords

INDINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY COMPOSITION; BODY DISTRIBUTION; BODY FAT; BODY MASS; BONE DENSITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY DIAGNOSIS; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIODIAGNOSIS; STANDARD; TREATMENT PLANNING;

EID: 23444441951     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1385/JCD:8:3:287     Document Type: Article

References (35)

1. Mazess RB, Barden HS, Bisek JP, Hanson J. 1990 Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 51:1106-1112.
2. Massip P, Marchou B, Bonnet E, Cuzin L, Montastruc JL. 1997 Lipodystrophia with protease inhibitors in HIV patients. Therapie 52:615.
3. Thiebaut R, Daucourt V, Mercie P, et al. 1999 Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 31:1482-1487.
4. Tebas P, Powderly WG, Claxton S, et al. 2000 Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14:F63-F67.
5. Tershakovec A, Frank I, Rader D. 2004 HIV-related lipodystrophy and related factors. Atherosclerosis 174:1-10.
6. Snead DB, Birge SJ, Kohrt WM. 1993 Age-related differences in body composition by hydrodensitometry and dual-energy X-ray absorptiometry. J Appl Physiol 74:770-775.
7. Heymsfield SB, Lichtman S, Baumgartner RN, et al. 1990 Body composition of humans: comparison of two improved four-compartment models that differ in expense, technical complexity, and radiation exposure. Am J Clin Nutr 52:52-58.
8. Carr A, Samaras K, Burton S, et al. 1998 A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:51-58.
9. Saint-Marc T, Partisani M, Poizot-Martin I, et al. 1999 A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13:1659-1667.
10. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. 1998 Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351:871-875.
11. Viraben R, Aquilina C. 1998 Indinavir-associated lipodystrophy. AIDS 12:F37-F39.
12. Charles MA, Basdevant A, Eschwege E. 2002 Prevalence of obesity in France: the situation in 2002 established from the OBEPI study. Ann Endocrinol 63:154-158.
13. Karlsson MK, Gardsell P, Johnell O, Nilsson BE, Akesson K, Obrant KJ. 1993 Bone mineral normative data in Malmo, Sweden. Comparison with reference data and hip fracture incidence in other ethnic groups. Acta Othop Scand 64:168-172.
14. Mazess RB, Barden HS, Drinka PJ, Bauwens SF, Orwoll ES, Bell NH. 1990 Influence of age and body weight on spine and femur bone mineral density in U.S. white men. J Bone Miner Res 5:645-652.
15. Miller J, Carr A, Smith D, et al. 2000 Lipodystrophy following antiretroviral therapy of primary HIV infection. AID 14:2406-2407.
16. Hadigan C, Meigs JB, Corcoran C, et al. 2001 Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32:130-139.
17. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. 1999 Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 13:735-737.
18. Martinez E, Mocroft A, Garcia-Viejo MA, et al. 2001 Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357:592-598.
19. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. 2001 Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ lymphocyte count and CD4+ lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J AIDS 27:30-34.
20. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. 1999 Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353:2093-2099.
21. Carr A, Cooper DA. 2000 Adverse effects of antiretroviral therapy. Lancet 356:1423-1430.
22. Graham N. 2000 Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J AIDS 25:4-11.
23. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. 2000 Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14:1309-1316.
24. Saint-Marc T, Partisani M, Poizot-Martin I, et al. 2000 Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 14:37-49.
25. Carr A, Miller J, Eisman JA , Cooper DA. 2001 Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 15:703-709.
26. Knobel H, Guelar A, Vallecillo G, Nogues X, Diez A. 2001 Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 15:807-808.
27. Bonnet E, Hervé R, Aquilina C, Obadia M, Massip P, Bernard J. 2001 Early diagnosis and follow-up of fat and bone distribution abnormalities by dual energy X-ray absorptiometry (DXA). 4th International Conference on Nutrition and HIV Infection and 2nd European Workshop on Lipodystrophy, Cannes, 2001.
28. Cirelli A, Cirelli G, Balsamo G, Masciangelo R, Stasolla A, Manni M. 2003 Body habitus changes, metabolic abnormalities, osteopenia and cardiovascular risk in patients treated for human immunodeficiency virus infection. Ann Ital Med Int 18:238-245.
29. McDermott AY, Shevitz A, Knox T, Roubenoff R, Kehayias J, Gorbach S. 2001 Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 74:679-686.
30. Amiel C, Ostertag A, Slama L, et al. 2004 BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19:402-409.
31. Mondy K, Yarasheski KE, Powderly WG, et al. 2003 Longitudinal evolution of bone mineral density and bone markers in human immudeficiency virus-infected individuals. Clin Infect Dis 36:482-490.
32. Arpadi S, Horlick M, Shane E. 2004 Metabolic bone disease in human immunodeficiency virus-infected children. J Clin Endocrinol Metab 89:21-23.
33. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. 2001 Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 15:1823-1829.
34. Tothill P, Laskey MA, Orphanidou CI, van Wijk M. 1999 Anomalies in dual energy X-ray absorptiometry measurements of total-body bone mineral during weight change using Lunar, Hologic and Norland instruments. Br J Radiol 72:661-699.
35. Kuhne CA, Heufelder AE, Hofbauer LC. 2001 Bone and mineral metabolism in human immunodeficiency virus infection. J Bone Miner Res 16:2-9.